Gerald G. Krueger

16.7k total citations · 5 hit papers
121 papers, 9.9k citations indexed

About

Gerald G. Krueger is a scholar working on Immunology, Dermatology and Rheumatology. According to data from OpenAlex, Gerald G. Krueger has authored 121 papers receiving a total of 9.9k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Immunology, 42 papers in Dermatology and 25 papers in Rheumatology. Recurrent topics in Gerald G. Krueger's work include Psoriasis: Treatment and Pathogenesis (86 papers), Dermatology and Skin Diseases (36 papers) and Autoimmune and Inflammatory Disorders Research (23 papers). Gerald G. Krueger is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (86 papers), Dermatology and Skin Diseases (36 papers) and Autoimmune and Inflammatory Disorders Research (23 papers). Gerald G. Krueger collaborates with scholars based in United States, Canada and United Kingdom. Gerald G. Krueger's co-authors include Steven R. Feldman, Cynthia Guzzo, Kim Papp, Mark Lebwohl, Richard G. Langley, Newman Yeilding, Lisa T. Dooley, Charles N. Ellis, Anna Beutler and Yuhua Wang and has published in prestigious journals such as New England Journal of Medicine, The Lancet and The Journal of Immunology.

In The Last Decade

Gerald G. Krueger

120 papers receiving 9.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

2008 1.1k citations Kim Papp, Richard G. Langley et al. profile →
A Large-Scale Genetic Association Study Confirms IL12B and Leads to the Identification of IL23R as Psoriasis-Risk Genes

2007 833 citations Michele Cargill, Steven J. Schrodi et al. The American Journal of Human Genetics profile →
A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis

2007 588 citations Gerald G. Krueger, Richard G. Langley et al. New England Journal of Medicine profile →
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

2005 553 citations Christian Antoni, Gerald G. Krueger et al. Annals of the Rheumatic Diseases profile →
Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled study

2009 462 citations Arthur Kavanaugh, Iain B. McInnes et al. Arthritis & Rheumatism profile →

Peers

Countries citing papers authored by Gerald G. Krueger

Since Specialization

Citations

This map shows the geographic impact of Gerald G. Krueger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerald G. Krueger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerald G. Krueger more than expected).

Fields of papers citing papers by Gerald G. Krueger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerald G. Krueger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerald G. Krueger. The network helps show where Gerald G. Krueger may publish in the future.

Co-authorship network of co-authors of Gerald G. Krueger

This figure shows the co-authorship network connecting the top 25 collaborators of Gerald G. Krueger. A scholar is included among the top collaborators of Gerald G. Krueger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerald G. Krueger. Gerald G. Krueger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Psoriasis Characteristics for the Early Detection of Psoriatic Arthritis 2021 ·The Journal of Rheumatology ·(unknown), Jessica A. Walsh, (unknown), (unknown), Benjamin Haaland, Kristina Callis Duffin, Gerald G. Krueger, Bing Feng	10
2	Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study) 2014 ·Annals of the Rheumatic Diseases ·Arthur Kavanaugh, Iain B. McInnes, Philip J. Mease, Gerald G. Krueger, Dafna D. Gladman, Désirée van der Heijde, Yiying Zhou, Jiandong Lu, Jocelyn H. Leu, Neil Goldstein, Anna Beutler	106
3	A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2 2012 ·Dermatology and Therapy ·Bruce Strober, Jennifer Clay Cather, David Cohen, Jeffrey Crowley, Kenneth B. Gordon, Alice B. Gottlieb, Arthur F. Kavanaugh, Neil J. Korman, Gerald G. Krueger, Craig L. Leonardi, Sergio Schwartzman, Jeffrey M. Sobell, Gary Solomon, Melodie Young	10
4	A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1 2012 ·Dermatology and Therapy ·Bruce Strober, Jennifer Clay Cather, David Cohen, Jeffrey Crowley, Kenneth B. Gordon, Alice B. Gottlieb, Arthur F. Kavanaugh, Neil J. Korman, Gerald G. Krueger, Craig L. Leonardi, Sergio Schwartzman, Jeffrey M. Sobell, Gary Solomon, Melodie Young	24
5	Development of a Disease Severity and Responder Index for Psoriatic Arthritis (PsA) — Report of the OMERACT 10 PsA Special Interest Group 2011 ·The Journal of Rheumatology ·Laura C. Coates, (unknown), Philip Helliwell, Philip J. Mease, Kristina Callis-Duffin, Gerald G. Krueger, Neil McHugh, Vibeke Strand, Dafna D. Gladman, Oliver FitzGerald	29
6	Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled study breakdown → 2009 ·Arthritis & Rheumatism ·Arthur Kavanaugh, Iain B. McInnes, Philip J. Mease, Gerald G. Krueger, Dafna D. Gladman, Juan J. Gómez‐Reino, Kim Papp, Julie Zrubek, S. Mudivarthy, M. Mack, Sudha Visvanathan, Anna Beutler	462
7	A Large-Scale Genetic Association Study Confirms IL12B and Leads to the Identification of IL23R as Psoriasis-Risk Genes breakdown → 2007 ·The American Journal of Human Genetics ·Michele Cargill, Steven J. Schrodi, Monica Chang, Verónica García, Rhonda Brandon, Kristina P. Callis, Nori Matsunami, Kristin Ardlie, Daniel Civello, Joseph J. Catanese, Diane U. Leong, (unknown), Linda McAllister, Christopher B. Hansen, (unknown), Stephen M. Prescott, Thomas J. White, Mark Leppert, Gerald G. Krueger, Ann B. Begovich	833
8	Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2 2007 ·Arthritis & Rheumatism ·Désirée van der Heijde, Arthur Kavanaugh, Dafna D. Gladman, Christian Antoni, Gerald G. Krueger, Cynthia Guzzo, Bin Zhou, Lisa T. Dooley, Kurt de Vlam, Piet Geusens, C. Birbara, D Halter, Anna Beutler, (unknown)	140
9	A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis breakdown → 2007 ·New England Journal of Medicine ·Gerald G. Krueger, Richard G. Langley, Craig L. Leonardi, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Lisa T. Dooley, Mark Lebwohl	588
10	Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial 2006 ·Journal of the American Academy of Dermatology ·Gerald G. Krueger, Boni E. Elewski, Kim Papp, Andrea Wang, Ralph Zitnik, Angelika Jahreis	39
11	Psoriasis assessment tools in clinical trials 2005 ·Annals of the Rheumatic Diseases ·Steven R. Feldman, Gerald G. Krueger	418
12	Current concepts and review of alefacept in the treatment of psoriasis 2004 ·Dermatologic Clinics ·Gerald G. Krueger	17
13	Potential of Tumor Necrosis Factor Inhibitors in Psoriasis and Psoriatic Arthritis 2004 ·Archives of Dermatology ·Gerald G. Krueger, Kristina P. Callis	69
14	Repeated courses of IM alefacept in psoriasis Rationale and design of an international study that mimics the clinical practice setting 2003 ·Journal of Investigative Dermatology ·Gerald G. Krueger, Kenneth B. Gordon, P.C.M. van de Kerkhof, Wolfram Sterry	7
15	Doxycycline‐inducible retroviral expression of green fluorescent protein in immortalized human keratinocytes 2002 ·Experimental Dermatology ·Pritmohinder S. Gill, Gerald G. Krueger, Donald E. Kohan	2
16	Selective targeting of T cell subsets: focus on alefacept – a remittive therapy for psoriasis 2002 ·Expert Opinion on Biological Therapy ·Gerald G. Krueger	59
17	Experimental Models for Psoriasis 1990 ·Journal of Investigative Dermatology ·Gerald G. Krueger, (unknown)	33
18	Immunology/Inflammation of the Skin--A 50-Year Perspective. 1989 ·Journal of Investigative Dermatology ·Gerald G. Krueger, Georg Stingl	4
19	Resistance to 12-0-Tetradecanoyl Phorbol 13-Acetate-Induced Mitogenesis in the Nude Mouse 1984 ·Pathobiology ·Donald A. Chambers, Rhonna L. Cohen, Julianne J. Sando, Gerald G. Krueger	1
20	Migration of Langerhans Cells and the Expression of la on Epidermal Cells Following the Grafting of Normal Skin to Nude Mice 1984 ·Pathobiology ·Gerald G. Krueger, Raymond A. Daynes, Lee K. Roberts, (unknown)	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact